ArticleJournal of molecular biology2016
Structure of a TCR-Mimic Antibody with Target Predicts Pharmacogenetics.
Article in Journal of molecular biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 69 citations in OpenAlex.
- Discovery and engineering of bispecific TCR-mimic antibodies targeting peptide-HLA complex.mAbs · 2026Article
- Article
- Article
- Bispecific NK-Cell Engager Targeting TP53 Mutation Through Integration of a TCR-mimic Antibody.MedComm · 2026Article
- Computational Design of a TCR-like Human VComputational and structural biotechnology journal · 2026Article
- Article
- A general system for targeting MHC class II-antigen complex via a single adaptable loop.Nature biotechnology · 2025Article
- Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application.Chinese medical journal · 2025Review
- Development of an innovative approach for early diagnosis of cervical cancer using TCR‑like antibodies targeting HPV18 E6 and E7 peptides.Molecular medicine reports · 2025Article
- T cell receptor-like antibody specifically targets and eliminates cells infected with cytomegalovirus.Journal of translational medicine · 2025Article
- A microfluidic bone marrow chip for the safety profiling of biologics in pre-clinical drug development.Communications biology · 2025Article
- Antigen-specific modulation of chronic experimental autoimmune encephalomyelitis in humanized mice by TCR-like antibody targeting autoreactive T-cell epitope.Life science alliance · 2025Article
- Review
- The physiological interactome of TCR-like antibody therapeutics in human tissues.Nature communications · 2024Article
- Experimental Structures of Antibody/MHC-I Complexes Reveal Details of Epitopes Overlooked by Computational Prediction.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Article
- Experimental structures of antibody/MHC-I complexes reveal details of epitopes overlooked by computational prediction.bioRxiv : the preprint server for biology · 2023Article
- Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1.Cancer immunology, immunotherapy : CII · 2023Article
- Challenges and solutions for therapeutic TCR-based agents.Immunological reviews · 2023Review
- Facile repurposing of peptide-MHC-restricted antibodies for cancer immunotherapy.Nature biotechnology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
Antibody therapies currently target only extracellular antigens. A strategy to recognize intracellular antigens is to target peptides presented by immune HLA receptors. ESK1 is a human, T-cell receptor (TCR)-mimic antibody that binds with subnanomolar affinity to the RMF peptide from the intracellular Wilms tumor oncoprotein WT1 in complex with HLA-A*02:01. ESK1 is therapeutically effective in mouse models of WT1(+) human cancers. TCR-based therapies have been presumed to be restricted to one HLA subtype. The mechanism for the specificity and high affinity of ESK1 is unknown. We show in a crystal structure that ESK1 Fab binds to RMF/HLA-A*02:01 in a mode different from that of TCRs. From the structure, we predict and then experimentally confirm high-affinity binding with multiple other HLA-A*02 subtypes, broadening the potential patient pool for ESK1 therapy. Using the crystal structure, we also predict potential off-target binding that we experimentally confirm. Our results demonstrate how protein structure information can contribute to personalized immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.